Search research articles
Contact Us
Filters
Showing results (311-320 of 368) with videos related to
Page
of 37
Sort By:
Alimentary Pharmacology & Therapeutics
|
November 25, 2016
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
J-F Colombel, B Jharap, W J Sandborn, et al.
Gut
|
November 22, 2005
Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation
D Philippe, D Chakass, X Thuru, et al.
Alimentary Pharmacology & Therapeutics
|
November 24, 2012
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
W J Sandborn, J-F Colombel, G D'Haens, et al.
The Journal of Experimental Medicine
|
April 3, 2001
Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies
P Desreumaux, L Dubuquoy, S Nutten, et al.
Alimentary Pharmacology & Therapeutics
|
January 24, 2017
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
L Vuitton, L Peyrin-Biroulet, J F Colombel, et al.
Mucosal Immunology
|
July 16, 2015
The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils
V Driss, M El Nady, M Delbeke, et al.
Alimentary Pharmacology & Therapeutics
|
April 28, 2017
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial
X Roblin, G Boschetti, N Williet, et al.
Revista De Gastroenterologia De Mexico
|
December 10, 2014
[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]
A Dignass, R Eliakim, F Magro, et al.
Alimentary Pharmacology & Therapeutics
|
October 1, 1996
Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody
V Canva-Delcambre, S Jacquot, E Robinet, et al.
Gut
|
February 16, 2005
Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study
S Baron, D Turck, C Leplat, et al.
Page
of 37
Search research articles
Search
Showing results (311-320 of 368) with videos related to
Sort By:
Page
of 37
Alimentary Pharmacology & Therapeutics
|
November 25, 2016
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
J-F Colombel, B Jharap, W J Sandborn, et al.
Gut
|
November 22, 2005
Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation
D Philippe, D Chakass, X Thuru, et al.
Alimentary Pharmacology & Therapeutics
|
November 24, 2012
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
W J Sandborn, J-F Colombel, G D'Haens, et al.
The Journal of Experimental Medicine
|
April 3, 2001
Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies
P Desreumaux, L Dubuquoy, S Nutten, et al.
Alimentary Pharmacology & Therapeutics
|
January 24, 2017
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
L Vuitton, L Peyrin-Biroulet, J F Colombel, et al.
Mucosal Immunology
|
July 16, 2015
The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils
V Driss, M El Nady, M Delbeke, et al.
Alimentary Pharmacology & Therapeutics
|
April 28, 2017
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial
X Roblin, G Boschetti, N Williet, et al.
Revista De Gastroenterologia De Mexico
|
December 10, 2014
[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]
A Dignass, R Eliakim, F Magro, et al.
Alimentary Pharmacology & Therapeutics
|
October 1, 1996
Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody
V Canva-Delcambre, S Jacquot, E Robinet, et al.
Gut
|
February 16, 2005
Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study
S Baron, D Turck, C Leplat, et al.
Page
of 37